The FDA approved Ionis Pharmaceuticals' ZANVASTRO (zilganersen) as the first disease-modifying treatment for Alexander disease in pediatric and adult patients. The approval follows trial data showing statistically significant stabilization of gait speed and grants Ionis a Priority Review Voucher alongside an exclusive position in an ultra-rare disease market.
The FDA approved Ionis' ZANVASTRO (zilganersen) as the first AxD treatment, with trial data showing a 33.3% gait speed benefit versus control.
"Today's approval of ZANVASTRO begins a new chapter for people living with Alexander disease and their families, who have long faced this relentlessly progressive and often fatal disease with no treatment options," Brett P. Monia, chief executive officer at Ionis, said.
The approval covers pediatric and adult patients with Alexander disease (AxD), an ultra-rare neurological disorder affecting approximately 1 in 1 to 3 million people worldwide. ZANVASTRO 50 mg is administered quarterly via intrathecal injection. The registration study met its primary endpoint in patients aged 5 years and older, with a least square mean difference of 33.3% on the 10-Meter Walk Test at Week 61 (p=0.041). Patients aged 2 to 4 years showed improvement on the Gross Motor Function Measure-88, while secondary and exploratory patient- and clinician-reported outcomes consistently favored the drug. Most adverse events were mild or moderate, with serious treatment-emergent events occurring less frequently in the ZANVASTRO group than in control.
The approval marks Ionis' first independent launch from its neurology pipeline and its second independent launch this year. The FDA also granted a Rare Pediatric Disease Priority Review Voucher, a transferable incentive that can accelerate review timelines for a future application or be sold. ZANVASTRO will be available in the U.S. in the coming weeks, with patient support delivered through the Ionis Every Step program. In June, Ionis licensed ex-U.S. rights to Recordati, with European and Japanese regulatory submissions expected in 2027.
AxD is caused by disease-causing variants in the GFAP gene that lead to overproduction and toxic accumulation of glial fibrillary acidic protein in astrocytes, damaging neurons and myelin over time. The disease typically leads to death within 14 to 25 years after symptom onset. ZANVASTRO is an RNA-targeted antisense oligonucleotide designed to reduce GFAP production at the source, addressing the underlying disease mechanism rather than managing symptoms.
The pivotal study enrolled 54 participants aged 1.5 to 53 years across 13 sites in eight countries, with most participants being children reflecting the early onset of AxD. Participants were randomized 2:1 to receive ZANVASTRO or control over a 60-week double-blind period. Common adverse reactions included vomiting, back pain, cough, headache, and post-lumbar puncture syndrome, with aseptic meningitis reported in some patients and requiring clinical evaluation per the label.
The approval gives Ionis an exclusive commercial position in a disease with no existing treatment options, and the Priority Review Voucher adds a potentially valuable transferable asset to its balance sheet. Investors will watch the company's webcast on Sept. 4 at 10 a.m. ET for launch commentary and any updated commercial guidance for the remainder of fiscal 2026.
This article is for informational purposes only and does not constitute investment advice.
